New York, New York 10021

  • Myelodysplastic Syndromes


RATIONALE: CC-5013 may slow the progression of myelodysplasia and allow the body to produce normal red blood cells. PURPOSE: Phase II trial to study the effectiveness of CC-5013 in treating patients who require red blood cell transfusions for anemia caused by myelodysplastic syndrome associated with a cytogenetic abnormality.

Study summary:

OBJECTIVES: Primary - Determine the efficacy of CC-5013, in terms of hematological improvement, in patients with red blood cell transfusion-dependent low- or intermediate-risk myelodysplastic syndromes and a del(5)(q31q33) cytogenetic abnormality. Secondary - Determine the safety of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral CC-5013 on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of low- or intermediate-risk myelodysplastic syndromes (MDS) associated with a del(5)(q31q33) cytogenetic abnormality - Cytogenetic abnormality may be an isolated cytogenetic finding (the 5q- syndrome) OR may be associated with other cytogenetic abnormalities - Red blood cell (RBC) transfusion-dependent anemia defined as having received at least 2 units of RBCs within the past 8 weeks PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 500/mm^3 - Platelet count at least 50,000/mm^3 - No clinically significant anemia due to iron, B_12, or folate deficiency, autoimmune or hereditary hemolysis, or gastrointestinal bleeding - If marrow aspirate not evaluable for storage iron, the following criteria must be met: - Transferrin saturation at least 20% - Serum ferritin at least 50 ng/mL Hepatic - Bilirubin no greater than 2.0 mg/dL - AST and ALT no greater than 3.0 times upper limit of normal Renal - Creatinine no greater than 2.5 mg/dL Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No prior grade 3 or greater allergic reaction or hypersensitivity to thalidomide - No prior grade 3 or greater rash or any desquamation (blistering) from thalidomide - No other serious medical condition, laboratory abnormality, or psychiatric illness that would preclude study participation or giving informed consent or confound study results - No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast PRIOR CONCURRENT THERAPY: Biologic therapy - No prior CC-5013 - More than 7 days since prior hematopoietic growth factors - No concurrent epoetin alfa for MDS Chemotherapy - More than 28 days since prior experimental or standard chemotherapy for MDS - No concurrent chemotherapy for MDS Endocrine therapy - More than 28 days since prior chronic use (greater than 2 weeks in duration) of more than physiologic doses of corticosteroids - No concurrent androgens for MDS Radiotherapy - Not specified Surgery - Not specified Other - More than 28 days since prior experimental or standard immunosuppressive or cytoprotective agents for MDS - More than 28 days since other prior experimental or standard drugs or therapy for MDS - No other concurrent investigational agents for MDS



Primary Contact:

Principal Investigator
Stephen D. Nimer, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.